|
|
News Breaks
|
February 10, 2012
|
| 10:29 EDT |  | SLXP |
| theflyonthewall.com: | Salix weakness is a buying opportunity, says Caris | | Caris said Salix is down on an FDA draft guidance report for Xifaxan generic requirements. The guidance requires generics only do a clinical study on 200mg for travelers diarrhea, not for 550mg, which is most of Salix's franchise. The firm recommends using Salix weakness as a buying opportunity. Reference Link :theflyonthewall.com |
|
|
News For SLXP From The Last 14 Days Check below for free stories on SLXP the last two weeks.
There are 2 items on the Fly with pertinent information.
Sign up for a free trial to see the rest of the stories you've been missing. |
|
May 16, 2012
|
| 09:49 EDT |  | SLXP |
| theflyonthewall.com: | Piper Jaffray's healthcare equipment and biotech analysts hold a conference call |
 Subscribe for More Information :theflyonthewall.com |
|
|
May 14, 2012
|
| 10:54 EDT | | SLXP |
| theflyonthewall.com: | Salix management to meet with JMP Securities | | Group dinner with management to be held in San Francisco on May 15 hosted by JMP Securities. :theflyonthewall.com |
|
|
|
|
|
